Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Promotes Head of Genomics Research to Senior Executive Post

NEW YORK, March 12 - Bristol-Myers Squibb has promoted its director of genomics-based pharmaceutical research, Elliot Sigal, to senior vice president in charge of drug discovery and exploratory development, the company said Monday.

The advancement for Sigal represents a "real sign of Elliot's leadership," said BMS spokeswoman Tracy Furey. "He is so highly regarded that he's now leading the whole discovery organization" at BMS' Pharmaceutical Research Institute, she said. 

Sigal joined BMS in 1997 as vice president for applied genomics, where he led the company's efforts to apply genomics to drug discovery. Prior to BMS, Sigal worked as CEO of Mercator Genetics, and earlier, as a faculty member in the department of medicine at the University of California, San Francisco.

Furey said the promotion did not indicate a greater shift in priorities towards genomics-based medicine, because "we have always made a significant investment in genomics." Instead, she said it was a major change for the company to place the entire research arm of the company under just one person.  
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.